サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1441407

ワクチンアジュバントの世界市場規模調査＆予測、タイプ別、用途別、投与別、地域別分析、2023-2030年

Global Vaccine Adjuvants Market Size study&Forecast, byType, by Application, by Administration and Regional Analysis, 2023-2030
出版日: | 発行: Bizwit Research & Consulting LLP | ページ情報: 英文 | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
ワクチンアジュバントの世界市場規模調査＆予測、タイプ別、用途別、投与別、地域別分析、2023-2030年
出版日: 2024年02月20日
発行: Bizwit Research & Consulting LLP
ページ情報: 英文
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のワクチンアジュバント市場は、2022年に約16億2,000万米ドルと評価され、予測期間2023-2030年には2.3%以上の健全な成長率で成長すると予測されています。

アジュバントは、ワクチンの有効性を高め、反応を改善するために予防接種に添加される成分です。ワクチンアジュバント市場の拡大は、以下の要因によるものです。

感染症の罹患率の増加、高齢者人口の増加、健康と予防接種に対する意識の高まりなどの要因です。

HIVや結核などの感染症予防に関するワクチン接種や予防接種に対する意識は、ある期間にわたって徐々に高まっています。米国疾病予防管理センターによると、世界でHIVに感染している人は3,900万人いましたが、ワクチンの普及数の増加により、この数は2%減少すると予想されています。さらに、世界保健機関（WHO）によると、結核に罹患している人は世界中で約1,060万人。感染症患者数の継続的な増加は、予防措置を用いて患者数を減らすための健康意識向上キャンペーンや予防接種プログラムの増加につながります。さらに、ヘルスケア施設の増加や製剤の進歩は、ワクチンアジュバント市場が成長する機会となっています。しかし、2020-2030年の予測期間を通じて、開発製造コストの高さがワクチンアジュバント市場の拡大を妨げる可能性があります。

ワクチンアジュバントの世界市場調査において考慮した主な地域は、アジア太平洋、北米、欧州、ラテンアメリカ、中東＆アフリカです。北米は、研究開発への投資の増加や重症疾患の増加などの要因により、2022年の市場を独占しました。その結果、急性疾患と慢性疾患の両方に対するワクチン接種が必要となっています。中東・アフリカは、医薬品の入手可能性を含む医療施設の絶え間ない強化や、満たされていない膨大なニーズに対応するための研究開発への資金調達の増加などの要因により、予測期間中に大きく成長すると予想されます。これにより、特定地域におけるワクチンアジュバントの市場シェアが上昇すると予測されます。

本調査の目的は、近年におけるさまざまなセグメントと国の市場規模を明らかにし、今後数年間の市場規模を予測することです。本レポートは、調査対象国における産業の質的・量的側面の両方を盛り込むよう設計されています。

また、市場の将来的な成長を規定する促進要因や課題などの重要な側面に関する詳細情報も提供しています。さらに、主要企業の競合情勢や製品提供の詳細な分析とともに、利害関係者が投資するためのミクロ市場における潜在的な機会も組み込んでいます。

目次

第1章 エグゼクティブサマリー

第2章 世界のワクチンアジュバント市場の定義と範囲

  • 調査目的
  • 市場の定義と範囲
    • 産業の進化
    • 調査範囲
  • 調査対象年
  • 通貨換算レート

第3章 世界のワクチンアジュバント市場力学

  • ワクチンアジュバント市場の影響分析（2020年～2030年）
    • 市場促進要因
      • 慢性疾患の増加
      • 高齢者人口の増加
      • 予防接種に対する意識の高まり
    • 市場の課題
      • ワクチンアジュバントの高コスト
    • 市場機会
      • 製剤の進歩
      • ヘルスケア施設の増加

第4章 世界のワクチンアジュバント市場産業分析

  • ポーターのファイブフォースモデル
  • ポーターのファイブフォース影響分析
  • PEST分析
  • 主な投資機会
  • 主要成功戦略
  • COVID-19影響分析
  • 破壊的動向
  • 業界専門家の視点
  • アナリストの結論・提言

第5章 ワクチンアジュバントの世界市場：タイプ別

  • 市場スナップショット
  • ワクチンアジュバントの世界市場：タイプ別、実績 - ポテンシャル分析
  • ワクチンアジュバントの世界市場タイプ別推定・予測 2020-2030年
  • ワクチンアジュバントの世界市場：サブセグメント別分析
    • 病原体
    • アジュバント乳剤
    • 粒子状
    • コンビネーション
    • その他

第6章 ワクチンアジュバントの世界市場：用途別

  • 市場スナップショット
  • ワクチンアジュバントの世界市場：用途別、実績 - ポテンシャル分析
  • ワクチンアジュバントの世界市場：用途別推定・予測 2020-2030年
  • ワクチンアジュバントの世界市場：サブセグメント別分析
    • 感染症
    • がん
    • その他

第7章 ワクチンアジュバントの世界市場：投与法別

  • 市場スナップショット
  • ワクチンアジュバントの世界市場：投与別、実績 - ポテンシャル分析
  • ワクチンアジュバントの世界市場：投与別推定・予測 2020-2030年
  • ワクチンアジュバントの世界市場：サブセグメント別分析
    • 経口
    • 皮内投与
    • 経鼻
    • 筋肉内
    • その他

第8章 ワクチンアジュバントの世界市場、地域分析

  • 主要国
  • 主な新興国
  • ワクチンアジュバント市場、地域別市場スナップショット
  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • スペイン
    • イタリア
    • その他欧州
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • 韓国
    • その他アジア太平洋地域
  • ラテンアメリカ
    • ブラジル
    • メキシコ
  • 中東・アフリカ
    • サウジアラビア
    • 南アフリカ
    • その他中東とアフリカ

第9章 競合情報

  • 主要企業のSWOT分析
  • 主要市場戦略
  • 企業プロファイル
    • GlaxoSmithKline plc.
      • 主要情報
      • 概要
      • 財務（データの入手可能性によります）
      • 製品概要
      • 最近の動向
    • Novavax, Inc.
    • Adjuvance Technologies, Inc.
    • SPI Pharma
    • Agenus, Inc.
    • CSL Limited
    • InvivoGen
    • AstrazenecaCroda
    • International Plc
    • Pfizer Inc

第10章 調査プロセス

  • 調査プロセス
    • データマイニング
    • 分析
    • 市場推定
    • 検証
    • 出版
  • 調査属性
  • 調査前提条件
図表

LIST OF TABLES

  • TABLE 1. Global Vaccine Adjuvants Market, report scope
  • TABLE 2. Global Vaccine Adjuvants Market estimates & forecasts by Region 2020-2030 (USD Billion)
  • TABLE 3. Global Vaccine Adjuvants Market estimates & forecasts by Type 2020-2030 (USD Billion)
  • TABLE 4. Global Vaccine Adjuvants Market estimates & forecasts by Application 2020-2030 (USD Billion)
  • TABLE 5. Global Vaccine Adjuvants Market estimates & forecasts by Administration 2020-2030 (USD Billion)
  • TABLE 6. Global Vaccine Adjuvants Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 7. Global Vaccine Adjuvants Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 8. Global Vaccine Adjuvants Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 9. Global Vaccine Adjuvants Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 10. Global Vaccine Adjuvants Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 11. Global Vaccine Adjuvants Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 12. Global Vaccine Adjuvants Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 13. Global Vaccine Adjuvants Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 14. Global Vaccine Adjuvants Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 15. Global Vaccine Adjuvants Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 16. U.S. Vaccine Adjuvants Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 17. U.S. Vaccine Adjuvants Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 18. U.S. Vaccine Adjuvants Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 19. Canada Vaccine Adjuvants Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 20. Canada Vaccine Adjuvants Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 21. Canada Vaccine Adjuvants Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 22. UK Vaccine Adjuvants Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 23. UK Vaccine Adjuvants Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 24. UK Vaccine Adjuvants Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 25. Germany Vaccine Adjuvants Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 26. Germany Vaccine Adjuvants Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 27. Germany Vaccine Adjuvants Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 28. France Vaccine Adjuvants Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 29. France Vaccine Adjuvants Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 30. France Vaccine Adjuvants Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 31. Italy Vaccine Adjuvants Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 32. Italy Vaccine Adjuvants Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 33. Italy Vaccine Adjuvants Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 34. Spain Vaccine Adjuvants Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 35. Spain Vaccine Adjuvants Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 36. Spain Vaccine Adjuvants Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 37. RoE Vaccine Adjuvants Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 38. RoE Vaccine Adjuvants Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 39. RoE Vaccine Adjuvants Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 40. China Vaccine Adjuvants Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 41. China Vaccine Adjuvants Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 42. China Vaccine Adjuvants Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 43. India Vaccine Adjuvants Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 44. India Vaccine Adjuvants Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 45. India Vaccine Adjuvants Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 46. Japan Vaccine Adjuvants Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 47. Japan Vaccine Adjuvants Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 48. Japan Vaccine Adjuvants Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 49. South Korea Vaccine Adjuvants Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 50. South Korea Vaccine Adjuvants Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 51. South Korea Vaccine Adjuvants Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 52. Australia Vaccine Adjuvants Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 53. Australia Vaccine Adjuvants Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 54. Australia Vaccine Adjuvants Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 55. RoAPAC Vaccine Adjuvants Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 56. RoAPAC Vaccine Adjuvants Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 57. RoAPAC Vaccine Adjuvants Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 58. Brazil Vaccine Adjuvants Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 59. Brazil Vaccine Adjuvants Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 60. Brazil Vaccine Adjuvants Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 61. Mexico Vaccine Adjuvants Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 62. Mexico Vaccine Adjuvants Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 63. Mexico Vaccine Adjuvants Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 64. RoLA Vaccine Adjuvants Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 65. RoLA Vaccine Adjuvants Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 66. RoLA Vaccine Adjuvants Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 67. Saudi Arabia Vaccine Adjuvants Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 68. South Africa Vaccine Adjuvants Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 69. RoMEA Vaccine Adjuvants Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 70. List of secondary sources, used in the study of global Vaccine Adjuvants Market
  • TABLE 71. List of primary sources, used in the study of global Vaccine Adjuvants Market
  • TABLE 72. Years considered for the study
  • TABLE 73. Exchange rates considered

List of tables and figures are dummy in nature, final lists may vary in the final deliverable

LIST OF FIGURES

  • FIG 1. Global Vaccine Adjuvants Market, research methodology
  • FIG 2. Global Vaccine Adjuvants Market, Market estimation techniques
  • FIG 3. Global Market size estimates & forecast methods
  • FIG 4. Global Vaccine Adjuvants Market, key trends 2022
  • FIG 5. Global Vaccine Adjuvants Market, growth prospects 2023-2030
  • FIG 6. Global Vaccine Adjuvants Market, porters 5 force model
  • FIG 7. Global Vaccine Adjuvants Market, pest analysis
  • FIG 8. Global Vaccine Adjuvants Market, value chain analysis
  • FIG 9. Global Vaccine Adjuvants Market by segment, 2020& 2030 (USD Billion)
  • FIG 10. Global Vaccine Adjuvants Market by segment, 2020& 2030 (USD Billion)
  • FIG 11. Global Vaccine Adjuvants Market by segment, 2020& 2030 (USD Billion)
  • FIG 12. Global Vaccine Adjuvants Market by segment, 2020& 2030 (USD Billion)
  • FIG 13. Global Vaccine Adjuvants Market by segment, 2020& 2030 (USD Billion)
  • FIG 14. Global Vaccine Adjuvants Market, regional snapshot 2020& 2030
  • FIG 15. North America Vaccine Adjuvants Market 2020& 2030 (USD Billion)
  • FIG 16. Europe Vaccine Adjuvants Market 2020& 2030 (USD Billion)
  • FIG 17. Asia pacific Vaccine Adjuvants Market 2020& 2030 (USD Billion)
  • FIG 18. Latin America Vaccine Adjuvants Market 2020& 2030 (USD Billion)
  • FIG 19. Middle East & Africa Vaccine Adjuvants Market 2020& 2030 (USD Billion)

List of tables and figures are dummy in nature, final lists may vary in the final deliverable

目次

Global Vaccine Adjuvants Market is valued at approximately USD 1.62 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 2.3% during the forecast period 2023-2030. Adjuvants are the ingredients that are added to the vaccinations to increase effectiveness of the vaccine and improve its response. The expansion of the Vaccine Adjuvants Market is due to

factors such as the increasing incidence of infectious diseases, growing geriatric population and rising awareness towards health and immunization.

The awareness towards vaccination and immunization regarding the prevention of infectious diseases such as HIV and tuberculosis (TB) has gradually increased over a period of time. according to Centers for Disease Control and Prevention, there were 39 million people in the world who were suffering with HIV and this number is expected to reduce by 2% due to rising number of vaccine prevalence. Furthermore, according to World Health Organization, approximately 10.6 million people suffered with Tuberculosis (TB) around the globe. The continuous increase in the number of patients of infectious diseases lead to the rise in health awareness campaigns and immunization programs to reduce the number by using the preventive measures. Moreover, rising healthcare facilities and advancements in formulations are the opportunities through which the Vaccine Adjuvants Market can grow. However, the high cost of production of development may hinder the expansion of the Vaccine Adjuvants Market throughout the forecast period of 2020-2030.

The key regions considered for the Global Vaccine Adjuvants Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 due to factors such as an increase in investments in R&D and a rise in severe diseases. Consequently, vaccination against both acute and chronic diseases become necessary. Middle East & Africa are expected to grow significantly over the forecast period due to factors such as constantly enhancing medical facilities, which include the availability of medications and increasing financing for research and development to meet the massive unfulfilled needs. This is projected to raise the market share of Vaccine Adjuvants in the particular region.

Major market player included in this report are:

  • GlaxoSmithKline plc.
  • Novavax, Inc.
  • Adjuvance Technologies, Inc.
  • SPI Pharma
  • Agenus, Inc.
  • CSL Limited
  • InvivoGen
  • AstrazenecaCroda International Plc
  • Pfizer Inc.

Recent Developments in the Market:

  • In May 2023, GSK plc declared that the US Food and Drug Administration approved Arexvy for the treatment of Respiratory Syncytial Virus (RSV) -related Lower Respiratory Tract Disease (LRTD) in patients 60 years of age and older. This is the first ever RSV immunization which is licensed for older people worldwide.
  • In March 2022, Croda International Plc confirmed the partnership with Statens Serum Institute. They may produce and commercialise a variety of patented cationic adjuvants, CAF which was developed by SSI.

Global Vaccine Adjuvants Market Report Scope:

  • Historical Data -2020 - 2021
  • Base Year for Estimation - 2022
  • Forecast period - 2023-2030
  • Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
  • Segments Covered - Type, Application, Administration, Region
  • Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa
  • Customization Scope - Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Type:

  • Pathogen
  • Adjuvant emulsion
  • Particulate
  • Combination
  • Others

By Application:

  • Infectious diseases
  • Cancer
  • Others

By Administration:

  • Oral
  • Intradermal
  • Intranasal
  • Intramuscular
  • Others

By Region:

  • North America
  • U.S.
  • Canada
  • Europe
  • UK
  • Germany
  • France
  • Spain
  • Italy
  • ROE
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • RoAPAC
  • Latin America
  • Brazil
  • Mexico
  • Middle East & Africa
  • Saudi Arabia
  • South Africa
  • Rest of Middle East & Africa

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Market Snapshot
  • 1.2. Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Billion)
    • 1.2.1. Vaccine Adjuvants Market, by Region, 2020-2030 (USD Billion)
    • 1.2.2. Vaccine Adjuvants Market, by Type,2020-2030 (USD Billion)
    • 1.2.3. Vaccine Adjuvants Market, by Application , 2020-2030 (USD Billion)
    • 1.2.4. Vaccine Adjuvants Market, by Administration, 2020-2030 (USD Billion)
  • 1.3. Key Trends
  • 1.4. Estimation Methodology
  • 1.5. Research Assumption

Chapter 2. Global Vaccine Adjuvants Market Definition and Scope

  • 2.1. Objective of the Study
  • 2.2. Market Definition & Scope
    • 2.2.1. Industry Evolution
    • 2.2.2. Scope of the Study
  • 2.3. Years Considered for the Study
  • 2.4. Currency Conversion Rates

Chapter 3. Global Vaccine Adjuvants Market Dynamics

  • 3.1. Vaccine Adjuvants Market Impact Analysis (2020-2030)
    • 3.1.1. Market Drivers
      • 3.1.1.1. Increasing incidence of chronic diseases
      • 3.1.1.2. Growing Geriatric Population
      • 3.1.1.3. Rising awareness towards immunization
      • 3.1.1.4.
    • 3.1.2. Market Challenges
      • 3.1.2.1. High Cost of Vaccine Adjuvants
    • 3.1.3. Market Opportunities
      • 3.1.3.1. Advancements in Formulation
      • 3.1.3.2. Rising Healthcare Facilities

Chapter 4. Global Vaccine Adjuvants MarketIndustry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
  • 4.2. Porter's 5 Force Impact Analysis
  • 4.3. PEST Analysis
    • 4.3.1. Political
    • 4.3.2. Economical
    • 4.3.3. Social
    • 4.3.4. Technological
    • 4.3.5. Environmental
    • 4.3.6. Legal
  • 4.4. Top investment opportunity
  • 4.5. Top winning strategies
  • 4.6. COVID-19 Impact Analysis
  • 4.7. Disruptive Trends
  • 4.8. Industry Expert Perspective
  • 4.9. Analyst Recommendation & Conclusion

Chapter 5. Global Vaccine Adjuvants Market, by Type

  • 5.1. Market Snapshot
  • 5.2. Global Vaccine Adjuvants Market by Type, Performance - Potential Analysis
  • 5.3. Global Vaccine Adjuvants Market Estimates & Forecasts by Type2020-2030 (USD Billion)
  • 5.4. Vaccine Adjuvants Market, Sub Segment Analysis
    • 5.4.1. Pathogen
    • 5.4.2. Adjuvant emulsion
    • 5.4.3. Particulate
    • 5.4.4. Combination
    • 5.4.5. Others

Chapter 6. Global Vaccine Adjuvants Market, by Application

  • 6.1. Market Snapshot
  • 6.2. Global Vaccine Adjuvants Market by Application , Performance - Potential Analysis
  • 6.3. Global Vaccine Adjuvants Market Estimates & Forecasts by Application 2020-2030 (USD Billion)
  • 6.4. Vaccine Adjuvants Market, Sub Segment Analysis
    • 6.4.1. Infectious diseases
    • 6.4.2. Cancer
    • 6.4.3. Others

Chapter 7. Global Vaccine Adjuvants Market, byAdministration

  • 7.1. Market Snapshot
  • 7.2. Global Vaccine Adjuvants Market by Administration, Performance - Potential Analysis
  • 7.3. Global Vaccine Adjuvants Market Estimates & Forecasts by Administraion2020-2030 (USD Billion)
  • 7.4. Vaccine Adjuvants Market, Sub Segment Analysis
    • 7.4.1. Oral
    • 7.4.2. Intradermal
    • 7.4.3. Intranasal
    • 7.4.4. Intramuscular
    • 7.4.5. Others

Chapter 8. Global Vaccine Adjuvants Market, Regional Analysis

  • 8.1. Top Leading Countries
  • 8.2. Top Emerging Countries
  • 8.3. Vaccine Adjuvants Market, Regional Market Snapshot
  • 8.4. North America Vaccine Adjuvants Market
    • 8.4.1. U.S.Vaccine Adjuvants Market
      • 8.4.1.1. Type breakdown estimates & forecasts, 2020-2030
      • 8.4.1.2. Application breakdown estimates & forecasts, 2020-2030
      • 8.4.1.3. Administration breakdown estimates & forecasts, 2020-2030
    • 8.4.2. CanadaVaccine Adjuvants Market
  • 8.5. Europe Vaccine Adjuvants Market Snapshot
    • 8.5.1. U.K. Vaccine Adjuvants Market
    • 8.5.2. Germany Vaccine Adjuvants Market
    • 8.5.3. France Vaccine Adjuvants Market
    • 8.5.4. Spain Vaccine Adjuvants Market
    • 8.5.5. Italy Vaccine Adjuvants Market
    • 8.5.6. Rest of EuropeVaccine Adjuvants Market
  • 8.6. Asia-PacificVaccine Adjuvants Market Snapshot
    • 8.6.1. China Vaccine Adjuvants Market
    • 8.6.2. India Vaccine Adjuvants Market
    • 8.6.3. JapanVaccine Adjuvants Market
    • 8.6.4. Australia Vaccine Adjuvants Market
    • 8.6.5. South Korea Vaccine Adjuvants Market
    • 8.6.6. Rest of Asia PacificVaccine Adjuvants Market
  • 8.7. Latin America Vaccine Adjuvants Market Snapshot
    • 8.7.1. Brazil Vaccine Adjuvants Market
    • 8.7.2. MexicoVaccine Adjuvants Market
  • 8.8. Middle East & AfricaVaccine Adjuvants Market
    • 8.8.1. Saudi ArabiaVaccine Adjuvants Market
    • 8.8.2. South AfricaVaccine Adjuvants Market
    • 8.8.3. Rest of Middle East & AfricaVaccine Adjuvants Market

Chapter 9. Competitive Intelligence

  • 9.1. Key Company SWOT Analysis
    • 9.1.1. Company 1
    • 9.1.2. Company 2
    • 9.1.3. Company 3
  • 9.2. Top Market Strategies
  • 9.3. Company Profiles
    • 9.3.1. GlaxoSmithKline plc.
      • 9.3.1.1. Key Information
      • 9.3.1.2. Overview
      • 9.3.1.3. Financial (Subject to Data Availability)
      • 9.3.1.4. ProductSummary
      • 9.3.1.5. Recent Developments
    • 9.3.2. Novavax, Inc.
    • 9.3.3. Adjuvance Technologies, Inc.
    • 9.3.4. SPI Pharma
    • 9.3.5. Agenus, Inc.
    • 9.3.6. CSL Limited
    • 9.3.7. InvivoGen
    • 9.3.8. AstrazenecaCroda
    • 9.3.9. International Plc
    • 9.3.10. Pfizer Inc

Chapter 10. Research Process

  • 10.1. Research Process
    • 10.1.1. Data Mining
    • 10.1.2. Analysis
    • 10.1.3. Market Estimation
    • 10.1.4. Validation
    • 10.1.5. Publishing
  • 10.2. Research Attributes
  • 10.3. Research Assumption